

2024-2029 UK Cancer Diagnostics Market Segmentation Analysis: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Competitive Analysis, Emerging Technologies, Latest Instrumentation, Growth Opportunities

<https://marketpublishers.com/r/2C04505BC60CEN.html>

Date: November 2024

Pages: 0

Price: US\$ 3,500.00 (Single User License)

ID: 2C04505BC60CEN

Abstracts

The report is available by section, market segment, and can be custom-tailored to your specific information needs and budget.

This new report from LeadingMarketResearch.com is based on a study of the major business opportunities emerging in the UK cancer diagnostics market during the next five years. The report examines trends in the UK market; reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers.

Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease.

During the next five years, the UK cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion.

UK Market Overview

Five-year test volume and sales projections.

- Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers.
- Estimated universe of laboratories performing cancer diagnostic testing.
- Cancer statistics, etiology and recent developments in Spain.

Business Opportunities and Strategic Recommendations

Specific new product development opportunities with potentially significant market appeal during the next five years.

- Design criteria for new products.
- Alternative market penetration strategies.
- Potential market entry barriers and risks.

Over 200 Current and Emerging Cancer Diagnostic Test Oncogenes

- Biochemical Markers
- Growth Factors
- Colony Stimulating Factors
- Hormones
- Immunohistochemical Stains
- Lymphokines

Supplier Shares, Sales and Volume Forecasts

Sales and market shares of major cancer diagnostic product suppliers by individual test. Five-year test volume and sales forecasts for major tumor markers by market segment, including:

Hospitals

Commercial/Private Laboratories

Instrumentation Review

Analysis of major molecular diagnostic and immunodiagnostic analyzers used for cancer testing, including their operating characteristics, features and selling prices.

Technology Assessment

Assessment of latest technologies and their potential applications for cancer diagnostic testing.

- Review of competing/complementing technologies.
- Extensive listings of companies, universities and research centers developing new cancer diagnostic tests and detection technologies.

Competitive Strategies

Strategic assessments of major suppliers and start-up firms developing innovative cancer diagnostic technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&

Contents

- I. Introduction
- II. Worldwide Market Overview
- III. Major Product Development Opportunities
 - A. Reagent Kits and Test Systems/Panels
 - B. Instrumentation
 - C. Computers, Software and Automation
 - D. Auxiliary Products
- IV. Design Criteria for Decentralized Testing Products
- V. Alternative Market Penetration Strategies
 - A. Internal Development
 - B. Collaborative Arrangements
 - C. University Contracts
 - D. Distribution Strategies
- VI. Potential Market Entry Barriers and Risks
 - A. Market Maturity
 - B. Cost Containment
 - C. Competition
 - D. Technological Edge and Limitations
 - E. Patent Protection
 - F. Regulatory Constraints
 - G. Decentralized Testing Market Challenges
- VII. Worldwide Market and Technology Overview
 - A. Cancer Statistics and Etiology

1. BREAST CANCER

2. LUNG CANCER

3. COLON AND RECTUM CANCER

4. PROSTATE CANCER

5. STOMACH CANCER

6. LEUKEMIA

7. LYMPHOMA

8. ORAL CANCER

9. SKIN CANCER

10. UTERINE CANCER

11. OVARIAN CANCER

12. BLADDER CANCER

(continued)

B. Major Current and Emerging Cancer Diagnostic Tests

1. INTRODUCTION

2. TUMOR MARKER CLASSIFICATION

3. ACTH

4. ALPHA-FETOPROTEIN (AFP)

5. BETA-2 MICROGLOBULIN

6. CA 15-3/27.29

7. CA 19-9

8. CA-125

9. CALCITONIN

10. CARCINOEMBRYONIC ANTIGEN (CEA)

11. ESTROGEN AND PROGESTERONE RECEPTORS

12. FERRITIN

13. GASTRIN

14. HUMAN CHORIONIC GONADOTROPIN (HCG)

15. INSULIN

16. NSE

17. OCCULT BLOOD

18. PAP SMEAR/HPV

19. PROSTATIC ACID PHOSPHATASE (PAP)

20. PROSTATE-SPECIFIC ANTIGEN (PSA)

21. SQUAMOUS CELL CARCINOMA ANTIGEN (SCC)

22. T AND B LYMPHOCYTES

23. TDT

24. THYROGLOBULIN

25. TISSUE POLYPEPTIDE ANTIGEN (TPA)

26. BIOCHEMICAL TUMOR MARKERS

27. ONCOGENES

- Abl/abl-bcr
- AIB1
- BCL-2
- BRCA1
- CD44
- C-fos
- C-myb
- C-myc
- CYP-17
- Erb-B

- HPC1
- N-myc
- P40
- P51
- P53
- PIK3CA
- PTI-1
- Ras
- Reg

I would like to order

Product name: 2024-2029 UK Cancer Diagnostics Market Segmentation Analysis: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Competitive Analysis, Emerging Technologies, Latest Instrumentation, Growth Opportunities

Product link: <https://marketpublishers.com/r/2C04505BC60CEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2C04505BC60CEN.html>